Dongmei Lu
Zhongshan, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial.
Journal: JAMA
Published: June 17, 2026
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China.
Journal: Lancet (London, England)
Published: April 23, 2026
TRIM28 orchestrates SUMO-ubiquitin crosstalk to stabilize PPARG and drive bladder cancer progression.
Journal: Cell death & disease
Published: November 05, 2025
Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 study.
Journal: Signal transduction and targeted therapy
Published: August 12, 2025
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial.
Journal: Lancet (London, England)
Published: July 23, 2025
Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial.
Journal: Nature communications
Published: April 21, 2025
Cadonilimab in advanced cervical cancer: the COMPASSION-16 trial - Authors' reply.
Journal: Lancet (London, England)
Published: April 14, 2025
Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.
Journal: Nature medicine
Published: March 27, 2025
CDCA3-MYC positive feedback loop promotes bladder cancer progression via ENO1-mediated glycolysis.
Journal: Journal of experimental & clinical cancer research : CR
Published: October 29, 2024
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.
Journal: Nature medicine
Published: September 29, 2024
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China.
Journal: Lancet (London, England)
Published: September 14, 2024
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China.
Journal: Lancet (London, England)
Published: August 28, 2024
Last Updated: 09/26/2026